Hashimoto's Disease: Definition and Treatment
Hashimoto's thyroiditis is a chronic autoimmune disorder where the immune system attacks the thyroid gland, causing lymphocytic infiltration and destruction of thyroid tissue, most commonly leading to hypothyroidism that requires lifelong levothyroxine replacement therapy.
What Is Hashimoto's Disease?
Hashimoto's thyroiditis (also called chronic autoimmune thyroiditis) is the most common cause of hypothyroidism in iodine-sufficient areas like the United States 1. The disease occurs 5-10 times more frequently in women than men and increases with age 1.
Pathophysiology
The disease results from a breakdown in immune tolerance to thyroid antigens, involving:
- Lymphocytic infiltration of the thyroid gland with sensitized T cells 1
- Autoantibody production against thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) 1, 2
- Progressive thyroid destruction leading to hormone deficiency 2
The condition stems from genetic predisposition triggered by environmental factors, with an imbalance in immune regulation—particularly involving Th17 cells and regulatory T cells 3.
Diagnosis
The diagnosis relies on three key elements:
- Elevated TSH with low or normal free T4
- Positive anti-thyroid antibodies (particularly anti-TPO antibodies, present in ~75% of cases) 1
- Characteristic ultrasound findings showing diffuse heterogeneous hypoechogenicity 2, 4
Critical diagnostic point: Among antibodies, only positive TPOAb tests are significantly associated with hypothyroidism and predict progression—4.3% per year with TPOAb versus 2.6% without 1. TPOAb positivity increases the risk of recurrent miscarriages and preterm birth 2-4 fold in pregnant women 2.
Clinical Presentation Stages
The disease progresses through distinct phases:
- Hashitoxicosis: Transient hyperthyroidism from release of stored hormones during thyroid destruction 2
- Euthyroidism: Compensated state where remaining tissue maintains normal hormone levels 2
- Subclinical hypothyroidism: Elevated TSH (>4.5 mIU/L) with normal free T4 5
- Overt hypothyroidism: Elevated TSH (usually >10 mIU/L) with low free T4 1
Treatment Approach
Primary Treatment: Levothyroxine
Levothyroxine is the definitive treatment for Hashimoto's thyroiditis once hypothyroidism develops 1, 2.
Dosing algorithm:
- Overt hypothyroidism: Start levothyroxine at 1.4-1.8 mcg/kg/day based on lean body mass and degree of preserved thyroid function 2
- Subclinical hypothyroidism with TSH >10 mIU/L: Levothyroxine therapy is reasonable given 5% annual progression rate and potential to prevent symptoms 5
- Subclinical hypothyroidism with TSH 4.5-10 mIU/L: Routine treatment is NOT recommended; instead, monitor TSH every 6-12 months 5
Important caveat for TSH 4.5-10 mIU/L: While guidelines recommend against routine treatment, a several-month trial may be considered if clear hypothyroid symptoms exist, but continuation requires documented symptomatic benefit 5. The likelihood of improvement is small and must be weighed against inconvenience, expense, and risks of therapy 5.
Special Population: Pregnancy
Pregnant women or those planning pregnancy with elevated TSH should be treated 5. This is critical because:
- TPOAb positivity increases miscarriage and preterm birth risk 2
- Only levothyroxine (not T3) should be used, as T3 does not adequately cross the fetal blood-brain barrier 2
Obtain TSH in pregnant women with family/personal history of thyroid disease, autoimmune disorders, type 1 diabetes, or symptoms suggesting hypothyroidism 5.
Adjunctive Therapies: Limited Evidence
Selenium supplementation is explicitly NOT recommended as treatment or prevention for hypothyroidism per guidelines 1. Despite some research suggesting potential benefits 6, 7, 4, the authoritative 2012 guideline specifically prohibits selenium use 1.
Dietary supplements and products marketed as "thyroid support" are not recommended 1.
Management of Hashitoxicosis
For the transient hyperthyroid phase, treatment focuses on symptom control with beta-blockers rather than antithyroid drugs 2.
Important Clinical Pitfalls
Monitor for overtreatment: 14-21% of patients on levothyroxine develop subclinical hyperthyroidism from excessive dosing 5.
Cancer surveillance: Hashimoto's increases risk of papillary thyroid cancer 1.6-fold and thyroid lymphoma 60-fold compared to the general population 2. Evaluate any discrete nodules appropriately.
Persistent symptoms despite normal TSH: Many patients report ongoing fatigue, cognitive issues, and reduced quality of life even with normalized TSH 8. This reflects the multidimensional impact of chronic autoimmunity and inflammation beyond thyroid hormone levels 8. However, there is insufficient evidence to recommend T3 combination therapy except in specific circumstances 2.
Associated autoimmune conditions: Screen for celiac disease, type 1 diabetes, vitiligo, and alopecia, which commonly coexist with Hashimoto's 4.